^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

Excerpt:
The fraction of tumor cells harboring ALK C1156Y was less than 7% in the pretreatment tumor, approximately 50% in the crizotinib-resistant tumor, and approximately 100% in the lorlatinib-resistant tumor.
DOI:
10.1056/NEJMoa1508887